Biochem/physiol Actions
CYP3cide is a mechanism-based inhibitor of cytochrome P4503A4 that can be used to distinguish the contributions of CYP3A4 versus CYP3A5 on drug metabolism. The IC50 values for inhibition of Midazolam 1′-Hydroxylase activity of recombinant CYP3A4 and CYP3A5 by CYP3cide are 0.3 and 17 mM, respectively.
Features and Benefits
This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
Other Notes
This compound was developed by Pfizer for ADME/Tox research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.
To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Pfizer is a registered trademark of Pfizer, Inc.
- UPC:
- 51111828
- Condition:
- New
- Availability:
- 3-5 Days
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- MPN:
- PZ0195-25MG
